Expand HURA Menu
HURA MENU

HURA Latest Press Releases

-- June 15, 2026 --

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers PRNewswire 7:50 AM

-- May 15, 2026 --

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PRNewswire 5:00 PM

-- May 12, 2026 --

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PRNewswire 7:30 AM

-- April 22, 2026 --

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 PRNewswire 7:30 AM

-- April 7, 2026 --

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations PRNewswire 7:45 AM

-- April 1, 2026 --

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update PRNewswire 7:45 AM

-- March 23, 2026 --

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers PRNewswire 7:45 AM

-- February 27, 2026 --

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement PRNewswire 7:30 AM

-- February 24, 2026 --

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences PRNewswire 5:20 PM

-- February 17, 2026 --

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers PRNewswire 7:45 AM

-- February 12, 2026 --

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PRNewswire 7:45 AM

-- February 2, 2026 --

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma PRNewswire 7:45 AM
Market Data Delayed 15 Minutes